{"title":"Neoadjuvant nivolumab plus chemotherapy improves overall survival in resectable NSCLC","authors":"Peter Sidaway","doi":"10.1038/s41571-025-01045-7","DOIUrl":null,"url":null,"abstract":"<p>Earlier data from the phase III CheckMate 816 trial led to the approval of nivolumab plus platinum-doublet chemotherapy as neoadjuvant therapy for patients with resectable non-small-cell lung cancer (NSCLC). Now, 5-year follow-up data from this trial confirm that this approach improves overall survival (OS).</p><p>A total of 358 patients with stage IB–IIIA NSCLC were randomly assigned (2:1) to receive three cycles of neoadjuvant nivolumab plus chemotherapy or chemotherapy alone, followed by surgery with optional adjuvant chemotherapy and/or radiotherapy permitted in both groups. The co-primary end points (pathological complete response (pCR) rate and event-free survival (EFS)) were met at a previous cutoff; overall survival (OS) was a key secondary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"61 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01045-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Earlier data from the phase III CheckMate 816 trial led to the approval of nivolumab plus platinum-doublet chemotherapy as neoadjuvant therapy for patients with resectable non-small-cell lung cancer (NSCLC). Now, 5-year follow-up data from this trial confirm that this approach improves overall survival (OS).
A total of 358 patients with stage IB–IIIA NSCLC were randomly assigned (2:1) to receive three cycles of neoadjuvant nivolumab plus chemotherapy or chemotherapy alone, followed by surgery with optional adjuvant chemotherapy and/or radiotherapy permitted in both groups. The co-primary end points (pathological complete response (pCR) rate and event-free survival (EFS)) were met at a previous cutoff; overall survival (OS) was a key secondary end point.
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
